Introduction: As serological immunomarkers like neopterin, β2-microglobulin,solubleIL-2receptor(sIL-2R)andIL-6have been described to be elevated in various malignancies, the aim of this study was to investigate wheth...Introduction: As serological immunomarkers like neopterin, β2-microglobulin,solubleIL-2receptor(sIL-2R)andIL-6have been described to be elevated in various malignancies, the aim of this study was to investigate whether they would be of diagnostic and prognostic value for leukemic and non-leukemic cutaneous T cell lymphoma (CTCL). Patients and Methods: Forty-one CTCL patients from the lymphoma clinics of the Department of Dermatology, University of Zürich, were tested for the serum levels of the above-mentioned immunomarkers at several time points, and clinical status and clinical outcome were recorded. Thirty-nine patients with CBCL and T cell inflammatory diseases served as controls. Results: The study revealed that neopterin, β2-MG and sIL-2R are significantly elevated in Se′zary syndrome, whereby sIL-2R seemed to be the most sensitive marker and is typically increased in Se′zary syndrome. Moreover, there is a correlation between tumor burden index values and serum parameters. Concerning the outcome of the disease (progression versus non-progression), only neopterin showed a significant prognostic value in non-leukemic CTCL patients. Conclusion: Serological immunomarkers are helpful tools in determining the tumor burden in CTCL and thus might be useful for disease monitoring during treatment. They may have prognostic value for predicting the clinical course.展开更多
We report the case of a 41-year-old patient with an aggressive cutaneous T-cell lymphoma (CTCL) initially presenting on histology as lymphocytic vasculitis. On repeated histological examination and by molecular biolog...We report the case of a 41-year-old patient with an aggressive cutaneous T-cell lymphoma (CTCL) initially presenting on histology as lymphocytic vasculitis. On repeated histological examination and by molecular biology work-up, the diagnosis of an unclassifiable CTCL could eventually be established. This atypical poorly differentiated lymphoma was of a CD4+CD8-CD56-phenotype and followed an unfavourable course. The patient died despite chemoand immunotherapy 7 months after the first consideration of lymphoma as diagnosis.展开更多
文摘Introduction: As serological immunomarkers like neopterin, β2-microglobulin,solubleIL-2receptor(sIL-2R)andIL-6have been described to be elevated in various malignancies, the aim of this study was to investigate whether they would be of diagnostic and prognostic value for leukemic and non-leukemic cutaneous T cell lymphoma (CTCL). Patients and Methods: Forty-one CTCL patients from the lymphoma clinics of the Department of Dermatology, University of Zürich, were tested for the serum levels of the above-mentioned immunomarkers at several time points, and clinical status and clinical outcome were recorded. Thirty-nine patients with CBCL and T cell inflammatory diseases served as controls. Results: The study revealed that neopterin, β2-MG and sIL-2R are significantly elevated in Se′zary syndrome, whereby sIL-2R seemed to be the most sensitive marker and is typically increased in Se′zary syndrome. Moreover, there is a correlation between tumor burden index values and serum parameters. Concerning the outcome of the disease (progression versus non-progression), only neopterin showed a significant prognostic value in non-leukemic CTCL patients. Conclusion: Serological immunomarkers are helpful tools in determining the tumor burden in CTCL and thus might be useful for disease monitoring during treatment. They may have prognostic value for predicting the clinical course.
文摘We report the case of a 41-year-old patient with an aggressive cutaneous T-cell lymphoma (CTCL) initially presenting on histology as lymphocytic vasculitis. On repeated histological examination and by molecular biology work-up, the diagnosis of an unclassifiable CTCL could eventually be established. This atypical poorly differentiated lymphoma was of a CD4+CD8-CD56-phenotype and followed an unfavourable course. The patient died despite chemoand immunotherapy 7 months after the first consideration of lymphoma as diagnosis.
